Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance

Emmanuel de Maistre; Fabienne Volot; Guillaume Mourey; Ludwig S. Aho; Catherine Ternisien; Marie-Elisabeth Briquel; Marie-Anne Bertrand; Brigitte Tardy; Birgit Frotscher; Philippe Nguyen; Laure Dumont; David Vandroux; Nathalie Hezard; Marc Trossaërt

doi:10.1160/TH14-02-0108

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 112(04): 825-830
DOI: 10.1160/TH14-02-0108

New Technologies, Diagnostic Tools and Drugs

Schattauer GmbH

Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance

Emmanuel de Maistre

¹Haematology Laboratory, University Hospital, Dijon, France

,

Fabienne Volot

²Haemophilia Center, University Hospital, Dijon, France

,

Guillaume Mourey

³Etablissement Français du Sang, Besançon, France

,

Ludwig S. Aho

⁴Epidemiology Department, University Hospital, Dijon, France

,

Catherine Ternisien

⁵Haematology Laboratory, University Hospital, Nantes, France

,

Marie-Elisabeth Briquel

⁶Haemophilia Center, University Hospital, Nancy, France

,

Marie-Anne Bertrand

⁷Haemophilia Center, University Hospital, Besançon, France

,

Brigitte Tardy

⁸Haematology Laboratory, University Hospital, Saint Etienne, France

,

Birgit Frotscher

⁶Haemophilia Center, University Hospital, Nancy, France

,

Philippe Nguyen

⁹Haematology Laboratory, University Hospital, Reims, France

,

Laure Dumont

¹⁰NVH Medicinal, Dijon, France

,

David Vandroux

¹⁰NVH Medicinal, Dijon, France

,

Nathalie Hezard

⁹Haematology Laboratory, University Hospital, Reims, France

,

Marc Trossaërt

⁵Haematology Laboratory, University Hospital, Nantes, France

› Author Affiliations

Abstract

Summary

The ristocetin cofactor activity assay (VWF:RCo) is the reference method for assessing von Willebrand factor (VWF) activity but remains difficult to perform, and the coefficient of variation of the method is high (about 20–30%). This study evaluated and compared the performance for measuring the VWF activity of two newly commercialised assays [VWF:Ac Innovance (VWF:Ac) and VWF:RCo Acustar (VWF:RCo Acu)] with the reference VWF:RCo aggregation in 123 pathological plasma samples. The correlation and concordance between both new tests (VWF:RCo-Acu and VWF:Ac) and the reference VWF:RCo were good. The results of the VWF activity to VWF antigen ratio were also comparable whatever the method for the classification of VWF deficiency in all patients. Our results showed that both new tests could replace the “gold standard” VWF:RCo in aggregometry with several benefits: they are fully automated, easier and faster to perform, better adapted to emergency situations if necessary.

Keywords

Willebrand activity assay - ristocetin cofactor activity - aggregometry - von Willebrand disease

Full Text

References

References
1 Sadler JE, Budde U, Eikenboom JC. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-2114.
2 Castaman G, Federici AB, Rodeghiero F. et al. Von Willebrand‘s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94-108.
3 Macfarlane DE, Stibbe J, Kirby EP. et al. Letter: A method for assaying von Wille-brand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-308.
4 Meijer P, Haverkate F. An external quality assessment program for von Wille-brand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32: 485-491.
5 Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21: 178-183.
6 Favaloro EJ, Mohammed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost 2010; 8: 2842-2844.
7 Verfaillie CJ, De Witte E, Devreese KM. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease. Int J Lab Hematol 2013; 35: 555-565.
8 Stufano F, Lawrie AS, La Marca S. et al. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia 2014; 20: 147-153.
9 Cabrera N, Moret A, Caunedo P. et al. Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method. Haemophilia 2013; 19: 920-925.
10 Lawrie AS, Stufano F, Canciani MT. et al. A comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia 2013; 19: 338-342.
11 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
12 Lin LI. A concordance correlation coefficient to evaluate reproducibility. Bio-metrics 1989; 45: 255-268.
13 Lasne D, Dey C, Dautzenberg MD. et al. Screening for von Willebrand disease: contribution of an automated assay for von Willebrand factor activity. Haemophilia 2012; 18: e158-163.
14 Trossaert M, Ternisien C, Lefrancois A. et al. Evaluation of an automated von Willebrand factor activity assay in von Willebrand disease. Clin Appl Thromb Hemost 2011; 17: E25-29.
15 Favaloro EJ, Lillicrap D, Lazzari MA. et al. von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia 2004; 10 (Suppl. 04) 164-168.
16 Federici AB. Therapeutic approaches to acquired von Willebrand syndrome. Expert Opin Investig Drugs 2000; 9: 347-354.
17 Nichols WL, Rick ME, Ortel TL. et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol 2009; 84: 366-370.